Selected References:
- Aliakbari F, et al. 2022. Relationship between long-term use of Ritalin and semen parameters in patients referred to psychiatric centres. First International Journal of Andrology, 54(11):1-6.
- Baker AS, et al. 2018. Management of attention deficit hyperactivity disorder dduring pregnancy. Obstet Gynecol Clin North Am, 45(3):495-509.
- Bateman B, et. al. 2015. Attention deficit hyperactivity medications during pregnancy and the risk of ccongenital cardiac malformations: A cohort study, abstracts, 368. Pharmacoepidemiol Drug Saf, 24:1–587.
- Besag F, (2014). ADHD treatment and pregnancy. Drug Saf, 37:397-408.
- Bolea-Alamanac B et. al. 2013. Methylphenidate use in pregnancy and lactation: a systematic review of evidence. Br J of Clin Pharm, 77(1):96-101.
- Briggs G, et. al. 2017. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Tenth edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health.
- Bro SP, et. al. 2015. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clinical Epi, 7:139-147.
- Diav-Citrin, O et. al. 2016. Methylphenidate in Pregnancy: A multicenter, prospective, comparative, cobservational study. J Clin Psychiatry, 77(9):1176-1181.
- Dideriksen D, et. al. 2013. First trimester in utero exposure to methylphenidate. Basic and Clin Pharm and Tox, 112:73-76.
- Golub M, et al. 2005. NTP CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamine. Birth Defects Res B Dev Reprod Toxicol, 74(6):471-584.
- Haervig KB, et. al. 2014. Use of ADHD medication during pregnancy from 1999-2010: a Danish register-based study. Pharmacoepidemiol and Drug Saf, 23:526-533.
- Humphreys C, et. al. 2007. Exposure to attention deficit hyperactivity disorder medications during pregnancy. Can Fam Physician, 53:1153-1155.
- Huybrechts KF, et al. 2018. Association between mmethylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the International Pregnancy Safety Study Consortium. JAMA Psychiatry, 75(2):167-175.
- Ilett KF, et. al. 2006. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. Br J of Clin Pharm, 63(3):371-375.
- Kallen B, et. al. 2013. The use of central nervous system active drugs during pregnancy. Pharmaceuticals, 6:1221-1286.
- Louik C, et. al. 2015. Increasing use of ADHD medications in pregnancy. Pharmacoepidemiol Drug Saf, 24(2):218-220.
- Madsen, KB, et al. 2023. In utero exposure to ADHD medication and long-term offspring outcomes. Mol Psychiatry, 28(4):1739-1746.
- Malo J et. al. 2015. ADHD drugs, pregnancy and lactation—increasing inquiries and need for more safety data. Birth Def Res Pt A, 103:458-464.
- Ornoy A, et al. 2020. The effects of drugs used for the treatment of attention deficit hyperactivity disorder (ADHD) on pregnancy outcome and breast feeding: a critical review. Curr Neuropharmacol, Online ahead of print.
- Pottegard A, et. al. 2014. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry, 75(1):e88-93.
- Spigset O, et. al. 2007. Excretion of methylphenidate in breast milk. Am J Psychiatry, 164:348.
- Suarez, EA, et al. 2024. Prescription stimulant use during pregnancy and risk of neurodevelopmental disorders in children. JAMA Psychiatry, e235073.
- Szpunar MJ, et al. 2023. Risk of major malformations in infants after first-trimester exposure to stimulants. J Clin Psychopharmacol, 43:326–332.
- Wajnberg R, et. al. 2011. Pregnancy outcome after in-utero exposure to methylphenidate: a prospective comparative cohort study. Repro Tox, 31:255-268.
